Navigation Links
Avanir Pharmaceuticals Announces FDA Acceptance of IND for AVP-786 for the Adjunctive Treatment of Major Depressive Disorder
Date:7/21/2014

ALISO VIEJO, Calif., July 21, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the U.S. Food and Drug Administration (FDA) accepted the company's Investigational New Drug (IND) application for a Phase II study assessing the safety and efficacy of AVP-786, Avanir's next generation compound. The company plans to initiate this study evaluating AVP-786 for the adjunctive treatment of major depressive disorder (MDD) during the third calendar quarter of 2014.

"The endorsement of this Phase II study by the division of Psychiatry Products at the FDA lends support for the expedited development path for AVP-786 and is allowing us to reference the extensive data generated during AVP-923 development programs. This is an important moment for the company, as this will be our first clinical study evaluating AVP-786 in patients," said Joao Siffert, MD, chief medical officer at Avanir Pharmaceuticals. "There are millions of patients with MDD who do not respond adequately to existing therapies.  With a mechanism of action addressing multiple neurotransmitter systems involved in depression, AVP-786, if approved, could offer a potential new treatment option for these patients. We look forward to initiating our clinical research program in the coming months."

The filing of this IND represents the first step in Avanir's plan to develop AVP-786 for a broad array of neurological and psychiatric conditions.

About the Study

This multicenter, randomized, double-blind, placebo-controlled proof-of-concept Phase II study will evaluate the efficacy and safety of AVP-786 in patients suffering from MDD who have had an inadequate response to commonly prescribed antidepressants, including selective serotonin reuptake inhibitors (SSRIs) and  serotonin-norepinephrine reuptake inhibitor
'/>"/>

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Avanir Pharmaceuticals Announces Presentation of Positive Early Results from PRISM II Study
2. Avanir Pharmaceuticals Pre-announces Preliminary Fiscal 2014 First Quarter Financial Information
3. Avanir Pharmaceuticals to Present at J.P. Morgan 32nd Annual Healthcare Conference
4. Quarterly Dividends, Clinical Trial Results, Dental Exhibition Updates, and Upcoming Presentation Schedules - Research Report Quest Diagnostics, Avanir, Sirona, Ligand and Genomic Health
5. Avanir Pharmaceuticals Reports Fiscal 2013 Fourth Quarter Financial and Year-End Business Results
6. Avanir Pharmaceuticals Announces Results for Phase II PRIME Study
7. Preliminary Financial Results, Quarterly Reports and Upcoming Conference Schedules - Research Report on Avanir, BioScrip, Chemed, Foundation Medicine, and Antares
8. Avanir Pharmaceuticals Pre-Announces Preliminary Fiscal 2013 Year End Financial Information
9. Avanir Pharmaceuticals to Host Investor Day on October 29, 2013
10. Avanir Pharmaceuticals Announces Enrollment of First Patient in Study of AVP-923 for the Treatment of Levodopa Induced Dyskinesia in Parkinsons Disease
11. Avanir Pharmaceuticals Announces Publication of AVP-825 Pharmacokinetic Data in Journal "Headache"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... , May 22, 2015 Electrophysiologist ... Institute recently traveled to Boston, MA ... at the 2015 Heart Rhythm Society conference. These ... to focus on the ideas, people and technology ... Convergent is a hybrid, minimally invasive cardiac operation ...
(Date:5/22/2015)... Texas , May 22, 2015 ... million in 2014 and is estimated to reach $90.7 million ... 2019. Browse through the TOC of North America ... segments, with the help of various tables and figures. ... receive 10% customization on this report.   ...
(Date:5/22/2015)... YORK , May 22, 2015  The ... of Zarxio (filgrastim-sndz) -- the first biosimilar product ... -- points toward growth in the contract ... The mainstream CMO industry is geared to the ... to produce major biopharmaceutical products. The healthcare market ...
Breaking Medicine Technology:St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 2St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 3North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 2North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4
... of ORMD 0801, Oral Insulin Capsule, ... on Type 1 Diabetics, ... a developer,of oral delivery systems, announced today that it has commenced Phase ... at the,Hadassah University Medical Center in Jerusalem, Israel., Oramed,s Phase 2A ...
... Cancer Research Aims to Raise Awareness about,the Importance of Clinical Trial Participation, ... with cancer would be receptive to participating in ... In a survey of 6,000 cancer patients, 85 percent were either unaware ... in a clinical trial was an option. ...
Cached Medicine Technology:Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics 2Video: The Looming Crisis in Cancer Drug Development: 97% of Adult Cancer Patients Do Not Take Advantage of Clinical Trial Programs 2Video: The Looming Crisis in Cancer Drug Development: 97% of Adult Cancer Patients Do Not Take Advantage of Clinical Trial Programs 3
(Date:5/25/2015)... Americas announces major investment in new technology and personnel ... Medical Answering Service customers. Through a combination of ... provides a seamless transition between a health care provider’s ... patient satisfaction. , Tunstall is pleased to ... expanded facilities and the latest telecommunication software and hardware ...
(Date:5/24/2015)... 24, 2015 Women's Excellence in ... loss. Although it is unclear about the etiology of ... factors such as metabolism, nutritional deficiencies, thyroid abnormalities and ... a comprehensive approach to evaluating the metabolic, nutritional and ... can help patients find a cause for their problem. ...
(Date:5/24/2015)... 24, 2015 The federal court ... ) has scheduled its next monthly Case Management ... litigation. According to court documents filed in the ... Conference will be convened on June 2, 2015, ... Product Liability Litigation - MDL No. 2545) , ...
(Date:5/24/2015)... (PRWEB) May 24, 2015 A ... indicator that the single best option for avoiding cardiovascular ... that fitness level was the single most powerful predictor ... variables such as diabetes and family history of premature ... maintaining lifelong heart and lung fitness. , The Importance ...
(Date:5/23/2015)... NY (PRWEB) May 23, 2015 On ... that, “the company has been the target of ... a part of the company’s ongoing Information Technology (IT) ... health insurers.” , The most notable attack on ... when Anthem Inc., the nation’s second largest health insurer, ...
Breaking Medicine News(10 mins):Health News:Tunstall Introduces New Medical Answering Service for the 21st Century Practice 2Health News:Women's Excellence Now Treats Menopausal Hair Loss 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 3Health News:Recent Mayo Clinic Studies Help to Highlight the Value of Cardio Testing 2Health News:Recent Mayo Clinic Studies Help to Highlight the Value of Cardio Testing 3Health News:One Headline Making Cyber Attack Sparks Discovery of Another 2Health News:One Headline Making Cyber Attack Sparks Discovery of Another 3Health News:One Headline Making Cyber Attack Sparks Discovery of Another 4
... and minority cancer patients through cancer treatment, called lay ... that prevent them from receiving quality care and achieving ... 2007, at the American Society for Therapeutic Radiology and ... Minority and low-income cancer patients continue to receive inferior ...
... Health & Science University researchers are reporting the discovery ... surgery and radiation therapy is used for patients with ... Surgery and radiotherapy shows an early response benefit. It ... for the first-line treatment, said Clifton David Fuller, M.D., ...
... Oct. 28 Disparities in access to health ... populations from receiving needed cancer services and often ... lasting impact of cancer education geared toward African-Americans, ... (UPMC), in partnership with The Centers for Healthy ...
... Efficiency and ... Treatment Consistency, CHICAGO, ... University of Nebraska Medical Center to save more than 83,percent ... prostate cancer. The automatic segmentation,software developed by BrainLAB replaces manual ...
... advice on safety, proper use , SUNDAY, Oct. 28 (HealthDay ... safety and best use of household cleaners and disinfectants from ... Surface Hygiene Fact Sheet outlines the safe, proper use ... germs can linger and the types of products available for ...
... A newborns chance for surviving a low-risk version of a ... study by Johns Hopkins surgeons. Babies with the condition have ... uncomplicated variant of the condition, where the hole is the ... percent of babies survive it. However the Hopkins findings suggest ...
Cached Medicine News:Health News:Patient navigators help minority, low-income cancer patients get life-saving treatments 2Health News:OHSU researchers: Surgery, radiation gives early survival advantage in bile duct cancer 2Health News:Education program leads to lasting improvement of cancer knowledge in African Americans 2Health News:iPlan(R) Automatic Segmentation Saves 25 Minutes of Treatment Planning Time for Each Prostate Cancer Patient at the University of Nebraska Medical Center 2
... FoamWrap Final Flexion Wraps restore full ... injury or when lost due to arthritic ... breathable, foam-lined material hugs the finger to ... to restore motion. One size. Sold in ...
One splint does it all....
... the physiological causes of minor knee pain ... works in concert with the motion of ... liner and patellar tendon and assisting in ... Semi-rigid plastic support with high density foam ...
... post-operative knee braces are designed to provide ... ,Adjustable and versatile, ROM braces are ... care professionals. The braces are extremely patient-friendly, ... dial combination hinges that allow you to ...
Medicine Products: